基于国际指南对选择性鼻咽癌患者行Ib区保护性调强放疗
本研究纳入450例根治性调强放疗的鼻咽癌患者,按国际指南选择性覆盖Ib区原则分组,390例仅满足后两条标准和/或Ib区受累但病理阴性者接受Ib区保护性调强放疗,中位随访112个月,5年和10年区域无复发生存率分别为95.4%和92.9%,仅4例(1.03%)出现Ib区复发。作者认为Ib区保护性调强放疗安全可行,建议进一步开展多中心前瞻性试验。
要点
- 390例仅II区受累伴包膜外侵犯和/或II区最大径大于2cm和/或Ib区受累但病理阴性者接受Ib区保护性调强放疗。
- 中位随访112个月,5年和10年区域无复发生存率分别为95.4%和92.9%,Ib区复发率1.03%(4/390)。
- 作者认为Ib区保护性调强放疗安全可行,建议进一步开展多中心前瞻性试验。
核心结论
- 对于仅有II区受累伴包膜外侵犯和/或II区最大径大于2cm和/或Ib区受累但病理阴性的患者,Ib区保护性调强放疗应该是安全可行的。
- 应进一步开展设计良好的多中心前瞻性试验。
研究设计与样本
- 本研究为单中心回顾性分析,纳入组织学证实的鼻咽癌患者,均接受根治性调强放疗。
- 共纳入450例患者,其中60例因符合国际指南前三条原则接受覆盖Ib区的调强放疗,390例仅符合后两条标准和/或Ib区受累但病理阴性者接受Ib区保护性调强放疗。
- Ib区受累者接受超声引导下穿刺,仅病理阳性者接受覆盖Ib区的调强放疗。
- 分析终点包括区域无复发生存率和Ib区复发率。
主要发现
- 390例接受Ib区保护性调强放疗的患者中位随访112个月(范围6至194个月),5年和10年区域无复发生存率分别为95.4%和92.9%。
- 截至删失时,22例患者出现区域复发(中位44.5个月),其中仅4例(4/390,1.03%)记录为Ib区复发。
临床怎么用
- 作者认为,对于仅有II区受累伴包膜外侵犯和/或II区最大径大于2cm和/或Ib区受累但病理阴性的患者,Ib区保护性调强放疗应该是安全可行的。
- 作者建议进一步开展设计良好的多中心前瞻性试验。
局限性
- 原文在结论中提出应进一步开展设计良好的多中心前瞻性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To investigate the feasibility of level Ib sparing in selected nasopharyngeal carcinoma (NPC) patients during intensity-modulated radiation therapy (IMRT) based on the International Guideline. PATIENTS AND MATERIALS: Patients with histologically-proven NPC who received definitive IMRT at our group were candidates for this analysis. Other eligibility criteria for analysis were designed according to the recommendation of International Guideline for selective coverage of level Ib. Survival outcomes focused on regional recurrence-free survival (RRFS) and level Ib recurrence rate were analyzed. RESULTS: A total of 450 patients were included, 60 of them received level Ib-covering IMRT due to the first three principles of the International Guideline according to our protocol. Of note, patients with level Ib involvement would receive ultrasound guided puncture, only those with positive pathological results would undergo level Ib-covering IMRT. For the remaining 390 patients who only fulfilled the last two criteria and/or level Ib involvement with negative pathological results, level Ib-sparing IMRT was delivered, with a median follow-up time of 112 months (range 6 to 194 months), reported 5- and 10-year RRFS were 95.4% and 92.9%, respectively. Twenty-two patients occurred regional recurrence at censorship (median 44.5 months), only 4(4/390, 1.03%) were recorded as level Ib recurrence. CONCLUSION: Level Ib-sparing IMRT should be safe and feasible for patients who only had level II involvement with ECE, and/or had a MAD of greater than 2 cm in level II, and/or level Ib involvement with negative pathological results. Further well-designed multi-center prospective trials should be conducted.
引用
- Guo Q, Xiao N, Xu H, et al. Level Ib sparing intensity-modulated radiation therapy in selected nasopharyngeal carcinoma patients based on the International Guideline. Radiother Oncol. 2021. PMID: 34973279. doi:10.1016/j.radonc.2021.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。